Twenty-four month comparison of apolipoproteins A-1, A-II, and B in contraceptive implant users (Norplant® and Implanon®) in Birmingham, United Kingdom

被引：11

作者：

Mascarenhas, L

van Beek, A

Bennink, HC

Newton, J

机构：

[1] Univ Cambridge, Addenbrookes Hosp, Dept Obstet & Gynaecol, Rosie Matern, Cambridge CB2 2SW, England

[2] NV Organon, NL-5340 BH Oss, Netherlands

[3] Birmingham Womens Hosp, Acad Dept Obstet & Gynaecol, Family Planning Clin, Birmingham, W Midlands, England

来源：

CONTRACEPTION | 1998年 / 58卷 / 04期

关键词：

contraceptive implant; etonogestrel/3-keto-desogestrel; levonorgestrel; serum apolipoproteins A-I; A-II and B; Norplant((R)); Implanon;

D O I：

10.1016/S0010-7824(98)00098-5

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

A e-year prospective, randomized study of 60 implant users was performed to evaluate fasting serial serum apolipoprotein A-I, A-II, and B levels before insertion and every 3 months in users of two contraceptive implants releasing levonorgestrel (Norplant(R)), and 3-ketodesogestrel/etonogestrel (Implanon(R)) in Birmingham, United Kingdom. All changes in serum apolipoprotein concentrations, irrespective of an increase or decrease, were smaller than one standard deviation of the mean concentration at baseline and did not exceed the normal range for the laboratory, thus implying no evidence of an increased risk of coronary heart disease. (C) 1998 Elsevier Science Inc. All rights reserved.

引用

页码：215 / 219

页数：5

共 23 条

[1]

BROWN MS, 1984, SCI AM, V251, P51

[2]

BURKMAN R, 1988, FERTIL STERIL, V48, P39

[3]

CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5

[4] A 5-YEAR CLINICAL-TRIAL OF LEVONORGESTREL SILASTIC IMPLANTS (NORPLANTTM) [J].